Deals channel feed

Boehringer In­gel­heim buys out next-gen ADC play­er NBE-Ther­a­peu­tics in a deal worth up to $1.4B+

5 years ago

'Are you guys out of vi­rol­o­gy?': Not hard­ly, says Gilead ex­ecs, as they buy a late-stage drug com­pa­ny for $1.7B

5 years ago

Pe­ter Thiel's Palan­tir scores con­tract with the FDA to speed up reg­u­la­to­ry re­views as de­lays keep grow­ing

5 years ago
Outsourcing

Boehringer In­gel­heim bags a con­tract man­u­fac­tur­er, adding mus­cles for can­cer vac­cine, on­colyt­ic virus pro­grams

5 years ago

Less than a year af­ter leav­ing Al­ler­gan, Brent Saun­ders has a $1.1B deal to take his SPAC pub­lic

5 years ago

With a po­ten­tial $458M per tar­get pay­day, Ali­gos teams up with Mer­ck hop­ing to re­verse biotech's re­cent NASH mal­adies

5 years ago

BioCryst bags $250M in a debt and roy­al­ty deal as the ex­ec­u­tive team preps a new drug launch for HAE

5 years ago
R&D

J&J taps the bis­pe­cif­ic ex­perts at Xen­cor for prostate can­cer dis­cov­ery pact, kick­ing off with $50M up­front

5 years ago

Bay­er picks up off-the-shelf CAR-T ap­proach from Atara, spot­light­ing a Memo­r­i­al Sloan Ket­ter­ing break­through

5 years ago
Cell/Gene Tx

Backed by a $200M in­vest­ment from a Ko­re­an con­glom­er­ate, Vivek Ra­maswamy has qui­et­ly built a ‘moth­er ship’ for vant cre­ation — with a whole new strat­e­gy in mind

5 years ago

Mer­ck KGaA bets big on DNA dam­age up­start, push­ing $30M up­front and hefty in­cen­tives for a Lyn­parza pi­o­neer

5 years ago

Ab­b­Vie eyes can­cer, im­munol­o­gy in lat­est pro­tein degra­da­tion pact, hand­ing Fron­tier Med­i­cines $55M up­front

5 years ago

J&J buys an ear­ly-stage gene ther­a­py for the eye — the on­ly known pro­gram for an un­der-the-radar biotech

5 years ago

As­traZeneca of­floads for­mer crown jew­el Crestor as it con­tin­ues to re­fo­cus on on­col­o­gy drugs

5 years ago

Re­gen­eron teams with gene ther­a­py pi­o­neer James Wil­son, adapt­ing its Covid-19 an­ti­body cock­tail to an AAV-based nasal spray

5 years ago
Coronavirus

With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

5 years ago

Bris­tol My­ers fronts new Schrödinger al­liance with $55M up­front, ex­pand­ing pre­ci­sion on­col­o­gy pro­file

5 years ago

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

5 years ago
Coronavirus

In an ap­par­ent R&D about-face, Eli Lil­ly part­ners with Pre­ci­sion Bio­Sciences on genome edit­ing in a deal worth up to near­ly $2.7B

5 years ago

As­traZeneca, Sam­sung quit race to de­vel­op Rit­ux­an copy­cat as ri­vals crowd out the mar­ket

5 years ago

No­var­tis bags Mesoblast's stem cell ther­a­py for ARDS, in­clud­ing in Covid-19, in a deal worth up to $1.2B+

5 years ago

Eli Lil­ly's Covid-19 part­ner Ab­Cellera pays $90M for some very spe­cial mice as Pe­ter Thiel jumps on the board and IPO ru­mors heat up

5 years ago

Pfiz­er hands Lian­Bio $70M to tag along Per­cep­tive's Chi­na play, with an eye to beef­ing up re­gion­al port­fo­lio

5 years ago
China

Rene­go­ti­ate the $6B CVR deal Bris­tol My­ers made for the Cel­gene buy­out? Caforio says that’s not hap­pen­ing

5 years ago
First page Previous page 82838485868788 Next page Last page
A service from the Financial Times